Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Sama Holding | Pharma | 36.7% | 83rd pct | 123 |
| Megaveti | Pharma | 27.9% | 70th pct | 123 |
| Inparm | Pharma | 11.9% | 41st pct | 123 |
| Denk Pharma Caucasus | Pharma | 4.1% | 24th pct | 123 |
| New Georgia - 555 | Pharma | 3.4% | 20th pct | 123 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2023 | Sama Holding | Inparm | New Georgia - 555 | Denk Pharma Caucasus | Megaveti |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 37.0% | 12.0% | 40.5% | 41.9% | 47.6% |
| EBITDA Margin | 36.7% | 11.9% | 3.4% | 4.1% | 27.9% |
| EBITDAR | 8,765 | 2,745 | 808 | 981 | 3,474 |
| EBITDAR Margin | 36.9% | 11.9% | 3.5% | 4.8% | 29.3% |
| EBIT Margin | 36.6% | 11.8% | 3.4% | 2.9% | 27.0% |
| Net Profit Margin | 37.4% | 12.6% | 2.9% | 2.9% | 25.2% |
| Operating Expense % of Sales | 0.4% | 0.2% | 37.2% | 37.9% | 19.8% |
| Returns | |||||
| Return on Assets (ROA) | 46.2% | 14.5% | 7.3% | 5.1% | 61.5% |
| Return on Equity (ROE) | 64.8% | 124.7% | 10.7% | 12.5% | 63.3% |
| ROIC [EBIT / Invested Capital] | 63.5% | 158.6% | 10.0% | 17.0% | 94.6% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 0.0% | 20.0% | 0.1% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.29x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 2.32x | 0.01x | 0.00x |
| Equity-to-Assets | 71.2% | 11.6% | 67.7% | 40.7% | 97.0% |
| Net Debt | -1 | -612 | 1,653 | -1,200 | -1,332 |
| Cash & Equivalents | 1 | 612 | 141 | 1,208 | 1,332 |
| Total Debt | N/A | N/A | 1,794 | 8 | N/A |
| Liquidity & working capital | |||||
| Current Ratio | 3.47x | 1.13x | 2.55x | 1.56x | 0.00x |
| Quick Ratio | 3.47x | 1.13x | 2.55x | 1.25x | 0.00x |
| Cash Ratio | 0.00x | 0.03x | 0.09x | 0.18x | 9.19x |
| Total Current Assets | 19,259 | 20,132 | 3,914 | 10,766 | 0 |
| Total Current Liabilities | 5,548 | 17,806 | 1,536 | 6,883 | 145 |
| Inventory | N/A | N/A | N/A | 2,128 | N/A |
| Trade Receivables | 18,017 | 17,963 | 3,084 | 6,324 | 555 |
| Trade Payables | 5,548 | 17,522 | 969 | 6,710 | 145 |
| Net Working Capital | 13,711 | 2,326 | 2,377 | 3,883 | -145 |
| Net Working Capital % of Revenue | 57.7% | 10.0% | 10.4% | 19.0% | -1.2% |
| Trade Working Capital | 12,469 | 440 | 2,114 | 1,742 | 410 |
| Trade Working Capital % of Revenue | 52.5% | 1.9% | 9.3% | 8.5% | 3.5% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | 5.59x | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | 65.3 | N/A |
| Receivables Turnover | 1.32x | 1.29x | 7.40x | 3.24x | 21.37x |
| Days Sales Outstanding (DSO) | 276.9 | 283.2 | 49.3 | 112.7 | 17.1 |
| Payables Turnover | 2.70x | 1.16x | 13.99x | 1.77x | 42.87x |
| Days Payable Outstanding (DPO) | 135.4 | 314.1 | 26.1 | 205.9 | 8.5 |
| Cash Conversion Cycle | 141.5 days | -30.9 days | 23.3 days | -27.9 days | 8.6 days |
| Asset Turnover | 1.23x | 1.15x | 2.54x | 1.77x | 2.44x |
| Cash flow & dividends | |||||
| Operating Cash Flow | -615 | 157 | 188 | 542 | 916 |
| Free Cash Flow (OCF − Capex proxy) | -615 | 157 | 188 | 121 | 916 |
| Cash Conversion (OCF / EBITDA) | -7.1% | 5.7% | 24.3% | 65.0% | 27.7% |
| Dividends Declared | N/A | N/A | N/A | 0 | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | 0.0% | N/A |